Solutions
HLA Presented Peptides
HLA peptides are typically characterized by highly sensitive mass spectrometers through a multi-step procedure depicted below.
We developed and validated a proteogenomics pipeline for neoantigen discovery from patient tumor samples. By integrating genomic data analysis with advanced proteomic technologies, this pipeline enables the identification of unique neoantigens resulting from tumor-specific mutations.
Benefits of working with us:
- Access to proprietary HLA-peptide binding predictors
- Vast experience in the copy number estimation of HLA peptides
- Availability of HLA-typed tissues for target validation and off-target studies
- Proprietary processes and materials that lead to high yield, high purity HLA peptide preparations that will ensure the success of your study
HLA peptide discovery
With state-of-the-art mass spectrometers, Alithea routinely detects 20-30’000 unique peptide sequences from single experiments providing a significantly larger snapshot of HLA peptidome than was possible just a few years ago. The technology is applicable to the study of HLA peptides from cells, tissues and from blood.
With Alithea’s HLA-Compass, we can run target discovery projects for you much faster and better than other proteomics service providers.
Absolute quantification with mass spectrometry is an analytical technique used to determine the exact concentration of target proteins or peptides within a sample. The technique relies on heavy stable isotope-labeled standards, that are spiked into the sample in known amounts and serve as internal references, allowing for the validation of analyte identification and quantification of its abundance.